Atai Beckley N.V. - 14 May 2021 Form 3 Insider Report for IntelGenx Technologies Corp.

Role
10%+ Owner
Signature
/s/ Florian Brand, Chief Executive Officer of ATAI Life Sciences B.V. and ATAI Life Sciences AG
Issuer symbol
N/A
Transactions as of
14 May 2021
Net transactions value
$0
Form type
3
Filing time
24 May 2021, 16:57:18 UTC
Next filing
28 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IGXT Common Stock, $0.00001 par value per share 37,300,000 14 May 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IGXT Warrant (Right to Buy) 14 May 2021 Common Stock, $0.00001 par value 22,380,000 $0.3500 Direct F1, F2
holding IGXT Warrant (Right to Buy) 14 May 2021 Common Stock, $0.00001 par value 130,000,000 Direct F1, F3
holding IGXT Warrant (Right to Buy) 14 May 2021 Common Stock, $0.00001 par value Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 See Exhibit 99.1
F2 See Exhibit 99.1
F3 See Exhibit 99.1
F4 See Exhibit 99.1

Remarks:

In April 2021, ATAI Life Sciences AG was acquired by ATAI Life Sciences B.V. as a consequence of a capital increase of ATAI Life Sciences B.V. in the context of which the shareholders of ATAI Life Sciences AG contributed and transferred their shares in ATAI Life Sciences AG as a contribution in kind to ATAI Life Sciences B.V., resulting in ATAI Life Sciences AG becoming a wholly-owned subsidiary of ATAI Life Sciences B.V. and the shareholders of ATAI Life Sciences AG becoming the shareholders of ATAI Life Sciences B.V. Accordingly, this Form 3 has been filed on behalf of ATAI Life Sciences AG and ATAI Life Sciences B.V.